Conclusions:
The VIABAHN stent graft is a safe, effective, and durable device for treating cephalic arch stenosis when venoplasty fails.
Summary: To determine the effectiveness of the VIABAHN stent graft to treat cephalic arch stenosis in patients with dysfunctional brachiocephalic arteriovenous fistulas after inadequate venoplasty. Between 2012 and 2015, patients with failed venoplasty of symptomatic cephalic arch stenosis received a VIABAHN stent graft and are evaluated this retrospective study. Follow-up venography was performed at approximately 3, 6, and 12 months. Data were retrospectively analyzed with patency estimated using Kaplan-Meier and log-rank methodology. There were 39 patients included. Technical and clinical success was 100%. Primary target lesion patency was 85% (95% confidence interval [CI], 69%-93%), 67% (95% CI, 50%-80%), and 42% (95% CI, 25%-57%) at 3, 6, and 12 months. There was no significant difference in patency with regard to sex or age (P ¼ .8 and P ¼ .6, respectively). Primary assisted patency was 95% (95% CI, 82%-99%) at 3, 6, and 12 months. Access circuit primary patency was 85% (95% CI, 69%-93%), 67% (95% CI, 50%-80%), and 42% (95% CI, 25%-57%) at 3, 6, and 12 months. There was no significant difference in patency between patients with the stent graft as the first treatment episode in the cephalic arch and those that had previous intervention at this site (P ¼ .98). There were 48 repeat venoplasty procedures performed in the cephalic arch to maintain patency, including seven repeat VIABAHN insertions. No complications were encountered.
Comments: Placement of a Viabahn stent that high in the venous circuit of an arteriovenous fistula can eliminate options for subsequent access reconstructions if the stent is placed into the central vein. The authors note that placement into the central vein of more than 1 to 3 mm is not desired but emphasizing this fact will help to prevent undesired consequences. It might be better to consider an open patch of the area to improve outflow and preserve the deep veins for subsequent access if any potential compromise of the central vein would result. Conclusions: Approximately 1 in 5 patients hospitalized for critical limb ischemia (CLI) and undergoing revascularization is readmitted within 30 days. Readmission risk is influenced by CLI presentation, patient demographics, comorbidities, and in-hospital complications, but not by the mode of revascularization.
Thirty-Day Readmissions
Summary: Thirty-day readmission rates have gained increasing importance as a key quality metric. A significant number of patients are hospitalized for the management of critical limb ischemia (CLI), but limited data are available on the incidence, predictors, and causes of 30-day readmission after the initial hospitalization for CLI. Hospitalizations for a primary diagnosis of CLI during which patients underwent endovascular or surgical therapy (revascularization and/or amputation) and were discharged alive were identified in the 2013 to 2014 Nationwide Readmissions Databases. Incidence, reasons, and costs of 30-day unplanned readmissions were determined. Hierarchical logistic regression models were used to identify independent predictors of 30-day readmissions. Included were 60,998 (national estimate, 135,110) index CLI hospitalizations (mean age, 68.9 6 11.9 years; 40.8% women; 24.6% for rest pain, 37.2% for ulcer, and 38.2% for gangrene). The 30-day readmission rate was 20.4%. Presentation with ulcer or gangrene, age $65 years, female sex, large hospital size, teaching hospital status, known coronary artery disease, heart failure, diabetes mellitus, chronic kidney disease, anemia, coagulopathy, obesity, major bleeding, acute myocardial infarction, vascular complications, and sepsis were identified as independent predictors of 30-day readmission. Mode of revascularization was not independently associated with readmissions. Infections (23.5%), persistent or recurrent manifestations of peripheral artery disease (22.2%), cardiac conditions (11.4%), procedural complications (11.0%), and endocrine issues (5.7%) were the most common reasons for readmission. The inflation-adjusted aggregate costs of 30-day readmissions for CLI during the study period was $624 million.
Comments: These types of studies are always concerning to me because readmissions for planned but delayed minor amputation or debridement may be mislabeled as unplanned and so misrepresent the actual readmission rates. That being said, a rate of 20% is well within the literature reported rate and so is a major concern and expense. It is interesting that an open revascularization was not a risk factor for readmission since long incisions with resulting wound complications are often reported as a significant component of the need for readmissions. It is logical to suggest that these patients require special attention (multidisciplinary) to address the many potential reasons for readmission, but in particular, infection control in consort with the wound care provider, to prevent the need for readmissions.
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Conclusions:
The incidence of myocardial infarction (MI) did not significantly decrease in the past decade and has been consistently associated with worse clinical outcomes. Further inquiry into why advanced perioperative care did not reduce cardiac complications is important to quality patient care.
Summary: Several advances in perioperative cardiac care have been adopted to hopefully improve the outcome of patients requiring vascular operations. To examine the temporal trends of MI following high-risk vascular procedures, this retrospective cohort study was performed using data collected from first of January 
